文献速递产科母胎医学

竞争风险模型在11-13周妊娠通过母体因素和生物标志物筛查子痫前期的准确性

Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation.
PubMed 文献 · Ultrasound Obstet Gynecol · 2017-05-14

这项前瞻性多中心研究纳入8775例单胎妊娠,评估11-13周联合母体因素、平均动脉压、子宫动脉搏动指数和血清胎盘生长因子的竞争风险模型筛查子痫前期的准确性。在10%假阳性率下,对<32周、<37周和≥37周子痫前期的检出率分别为100%、75%和43%,与模型开发数据集估计的检出率相似。

要点

  • 联合筛查对<32周子痫前期检出率达100%(95% CI 80-100%),对<37周为75%(95% CI 62-85%)。
  • 对≥37周子痫前期检出率为43%(95% CI 35-50%),低于早产型。
  • 检出率与模型开发数据集估计值相似,支持该模型用于早孕期筛查早产型子痫前期。

核心结论

  • 在11-13周联合评估母体因素和生物标志物可有效筛查早产型子痫前期。

研究设计与样本

  • 前瞻性多中心首孕期子痫前期筛查研究,纳入8775例单胎妊娠。
  • 使用先前发表的算法计算每个个体的子痫前期特异风险。

主要发现

  • 研究人群中239例(2.7%)发生子痫前期,其中<32周17例(0.2%)、<37周59例(0.7%)、≥37周180例(2.1%)。
  • 在10%假阳性率下,联合母体因素、平均动脉压、子宫动脉搏动指数和血清胎盘生长因子筛查的检出率:<32周为100%(95% CI 80-100%),<37周为75%(95% CI 62-85%),≥37周为43%(95% CI 35-50%)。
  • 模型开发数据集估计的检出率:<32周为89%(95% CI 79-96%),<37周为75%(95% CI 70-80%),≥37周为47%(95% CI 44-51%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the diagnostic accuracy of a previously developed model for prediction of pre-eclampsia (PE) by a combination of maternal factors and biomarkers at 11-13 weeks' gestation. METHODS: This was a prospective first-trimester multicenter study of screening for PE in 8775 singleton pregnancies. A previously published algorithm was used for the calculation of patient-specific risk of PE in each individual. The detection rates (DRs) and false-positive rates (FPRs) for delivery with PE < 32, < 37 and ≥ 37 weeks were estimated and compared with those for the dataset used for development of the algorithm. RESULTS: In the study population, 239 (2.7%) cases developed PE, of which 17 (0.2%), 59 (0.7%) and 180 (2.1%) developed PE < 32, < 37 and ≥ 37 weeks, respectively. With combined screening by maternal factors, mean arterial pressure, uterine artery pulsatility index and serum placental growth factor, the DR was 100% (95% CI, 80-100%) for PE < 32 weeks, 75% (95% CI, 62-85%) for PE < 37 weeks and 43% (95% CI, 35-50%) for PE ≥ 37 weeks, at a 10% FPR. These DRs were similar to the estimated rates for the dataset used for development of the model: 89% (95% CI, 79-96%) for PE < 32 weeks, 75% (95% CI, 70-80%) for PE < 37 weeks and 47% (95% CI, 44-51%) for PE ≥ 37 weeks. CONCLUSION: Assessment of a combination of maternal factors and biomarkers at 11-13 weeks provides effective first-trimester screening for preterm PE. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. O'Gorman N, Wright D, Poon LC, et al. Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. Ultrasound Obstet Gynecol. 2017. PMID: 28067011. doi:10.1002/uog.17399

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。